BMRN:
Analysis & Opinions
-
January 10, 2013
BioMarin Pharmaceutical Inc. (BMRN) recently acquired privately held biotechnology company, Zacharon ...
-
January 02, 2013
The market is having a good day so far: the Nasdaq has risen 2.3%; the S&P 500 is up 1.8%; and the Dow has climbed ...
-
December 10, 2012
On a good day for the market, the Nasdaq is trading up 0.6%, the S&P 500 is up 0.2% and the Dow has increased 0.3%. ...
-
November 05, 2012
This morning, the Nasdaq has climbed 0.1%, the S&P 500 has declined 0.3% and the Dow has slipped 0.3%. The Nasdaq ...
-
November 05, 2012
The Nasdaq has moved up 0.1%, the S&P 500 has declined 0.3% and the Dow has slipped 0.3% so far today. The ...
-
October 26, 2012
BioMarin Pharmaceutical Inc.'s (BMRN) third quarter 2012 loss of 4 cents per share was narrower than the Zacks ...
-
October 23, 2012
It's been a bad day for the market after the morning's trading. The Nasdaq has decreased 0.8%; the S&P 500 is down ...
-
September 28, 2012
BioMarin Pharmaceutical Inc. (BMRN) recently announced the completion of a phase I study, which evaluated its ...
-
September 27, 2012
BioMarin Pharmaceutical Inc. (BMRN) recently announced preliminary results from a phase II program of PEG-PAL ...
-
September 10, 2012
The Nasdaq has slipped 0.6%, the S&P 500 is unchanged and the Dow is trading up 0.1% after the morning's trading. ...
-
August 20, 2012
The market is having a bad day so far: the Nasdaq has slipped 0.2%; the S&P 500 is down 0.3%; and the Dow is trading ...
-
August 02, 2012
BioMarin Pharmaceutical Inc.'s (BMRN) second quarter 2012 loss of 27 cents per share was wider than the Zacks ...
-
June 02, 2012
BioMarin Pharmaceutical Inc. (BMRN) recently announced the pricing of an underwritten public offering of 6.5 million ...
-
September 28, 2011
Explore five stocks making new highs. Is this a case of overvalue, or could investors buy high and sell even higher?
-
August 17, 2011
In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
-
July 02, 2010
If biotech companies are buying each other, should investors get in on the action?
-
April 15, 2009
Despite positive Phase 3 results, this medicine-maker's valuation is excessive and its new drug won't make it to ...
-
June 20, 2008
Stocks that can string together many quarters of positive earnings surprises are usually rewarded. Learn why the ...
